0455.HK HKSE
Tianda Pharmaceuticals Limited
1W: -8.5%
1M: +6.3%
3M: +38.8%
YTD: +14.6%
1Y: -34.1%
3Y: -50.3%
5Y: -41.9%
HK$0.12 ($0.02)
-0.00 (-1.67%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$323M
-2.1% ▼
5Y CAGR: -7.4%
Gross Profit
$133M
-12.3% ▼
5Y CAGR: -12.4%
Operating Income
-$54M
+0.1% ▲
Net Income
-$70M
-14.1% ▼
EPS (Diluted)
$-0.03
-14.4% ▼
EBITDA
-$54M
-9.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $510M | $547M | $532M | $330M | $323M |
| YoY Growth | +7.5% | +7.2% | -2.7% | -38.0% | -2.1% |
| Cost of Revenue | $269M | $295M | $277M | $178M | $190M |
| Gross Profit | $241M | $252M | $256M | $152M | $133M |
| Gross Margin | 47.3% | 46.0% | 48.0% | 46.1% | 41.3% |
| R&D Expenses | $16M | $36M | $13M | $13M | $8M |
| SG&A Expenses | $269M | $286M | $271M | $193M | $179M |
| Operating Expenses | $283M | $322M | $285M | $206M | $187M |
| Operating Income | -$39M | -$70M | -$29M | -$54M | -$54M |
| Operating Margin | -7.6% | -12.8% | -5.5% | -16.4% | -16.7% |
| Interest Expense | $725K | $7M | $5M | $5M | $4M |
| Income Before Tax | -$28M | -$64M | -$26M | -$54M | -$69M |
| Tax Expense | -$6M | -$5M | -$689K | $7M | $926K |
| Net Income | -$22M | -$55M | -$24M | -$61M | -$70M |
| Net Margin | -4.3% | -10.0% | -4.5% | -18.6% | -21.7% |
| EPS (Diluted) | $-0.01 | $-0.03 | $-0.01 | $-0.03 | $-0.03 |
| EBITDA | -$5M | -$20M | $16M | -$49M | -$54M |
| Shares Outstanding | 2.15B | 2.15B | 2.15B | 2.15B | 2.15B |